Calon Cardio-Technology

Calon Cardio-Technology

Developing the next generation of implantable micro- pump for the treatment of heart failure. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
€6—9m (Dealroom.co estimates May 2015.)
Company register number 06166938
Swansea Wales (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2012201320142015201620172018
Revenues---<1m<1m-<1m
% growth----(89 %)--
EBITDA(<1m)(2.3m)(1.9m)(2.2m)(3.2m)(1.9m)(1.3m)
% EBITDA margin---(479 %)(6434 %)-(13220 %)
Profit(<1m)(2.2m)(1.8m)(1.8m)(3.1m)(1.8m)(<1m)
% profit margin---(392 %)(6221 %)-(6427 %)

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound

£1.5m

Series B

£1.2m

Seed

£490k

Grant
Total Funding€3.8m

Recent News about Calon Cardio-Technology

Edit
More about Calon Cardio-Technologyinfo icon
Edit

Calon Cardio Technology specializes in developing advanced heart pumps, specifically Left Ventricular Assist Devices (LVADs), aimed at treating chronic heart failure. The company operates in the medical device market, focusing on patients suffering from severe heart conditions who require mechanical circulatory support. Calon Cardio's primary clients are healthcare providers and hospitals that treat patients with chronic heart failure, a condition affecting around 26 million people in the developed world.

The business model revolves around the research, development, and eventual commercialization of their LVAD technology. Calon Cardio is currently seeking investment to proceed to first-in-human studies, which is a critical step towards bringing their product to market. Revenue will be generated through the sale of these devices to medical institutions and possibly through partnerships or licensing agreements with larger medical device companies.

Calon Cardio's innovative approach addresses the limitations of early-generation pumps, which were large, heavy, and required highly invasive surgery. Their technology aims to offer a more reliable and durable solution with fewer adverse effects like haemolysis and thrombosis.

Keywords: heart pump, LVAD, chronic heart failure, mechanical circulatory support, medical device, heart transplant alternative, healthcare providers, investment, human studies, advanced treatment.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.